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Abstract Acute normocapnic hypoxemia can cause func-
tional renal insufficiency by increasing renal vascular
resistance (RVR), leading to renal hypoperfusion and
decreased glomerular filtration rate (GFR). Insulin-like
growth factor 1 (IGF-1) activity is low in fetuses and
newborns and further decreases during hypoxia. IGF-1
administration to humans and adult animals induces pre-
and postglomerular vasodilation, thereby increasing GFR
and renal blood flow (RBF). A potential protective effect of
IGF-1 on renal function was evaluated in newborn rabbits
with hypoxemia-induced renal insufficiency. Renal function
and hemodynamic parameters were assessed in 17 anesthe-
tized and mechanically ventilated newborn rabbits. After
hypoxemia stabilization, saline solution (time control) or
IGF-1 (1 mg/kg) was given as an intravenous (i.v.) bolus,
and renal function was determined for six 30-min periods.
Normocapnic hypoxemia significantly increased RVR
(+16%), leading to decreased GFR (−14%), RBF (−19%)
and diuresis (−12%), with an increased filtration fraction
(FF). Saline solution resulted in a worsening of parameters
affected by hypoxemia. Contrarily, although mean blood
pressure decreased slightly but significantly, IGF-1 pre-
vented a further increase in RVR, with subsequent
improvement of GFR, RBF and diuresis. FF indicated
relative postglomerular vasodilation. Although hypoxemia-
induced acute renal failure was not completely prevented,
IGF-1 elicited efferent vasodilation, thereby precluding a
further decline in renal function.
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Introduction
Perinatal asphyxia is a leading cause of neonatal morbidity
and mortality. Acute renal failure (ARF) related to perinatal
asphyxia accounts for the majority of ARF cases in
newborns, along with hypovolemia and hypotension [1,
2]. In clinical observations and preclinical animal models,
acute normocapnic hypoxemia can induce functional renal
insufficiency by increasing the renal vascular resistance
(RVR), thus leading to renal hypoperfusion and decreased
glomerular filtration rate (GFR). The pathophysiologic
mechanisms of this vasomotor nephropathy involve numerous
local and humoral vasoactive agents. Previous studies from
our laboratory have demonstrated that hypoxemia induces an
alteration in the balance of local vasomediators in the newborn
rabbit’s kidney, including the vasoconstrictors adenosine and
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angiotensin II [3–5], as well as the vasodilator nitric oxide
(NO) [6].
Insulin-like growth factor 1 (IGF-1) is a single-chain
peptide growth factor with metabolic, mitogenic, anti-apoptotic
and vasoactive properties [7, 8]. The growth hormone (GH)/
IGF-1 axis is the key endocrine and paracrine/autocrine
regulator of both pre- and postnatal whole-body growth [9–
12]. Plasma concentrations of IGF-1 and IGF-2 in the fetus
positively correlate with birth weight in numerous species,
including humans, primates, sheep, pigs, rodents and rabbits
[13, 14].
In the adult kidney, in situ hybridization studies have
shown that synthesis of IGF-1 occurs in various parts of the
nephron [7], with IGF-1 receptors being present in glomeruli
and on the basolateral membrane of renal proximal tubular
cells [15–17]. Data from a rabbit model of intra-uterine
growth retardation (IUGR) indicate that the rabbit fetal
kidney expresses IGF-1 mRNA during late gestation and at
birth [13]. In the developing rat kidney IGF-1 mRNA levels
show a linear increase throughout the first month of postnatal
life [1]. Likewise, in the developing rabbit tubular IGF-1
receptor, mRNA levels increase during terminal maturation
of the tubules in the first three postnatal weeks [18].
Serum IGF-1 levels have been shown to be reduced in
hypoxic–ischemic newborns [19, 20]. In the fetal sheep,
asphyxia induced by complete umbilical cord occlusion for
30 min leads to a decrease in circulating levels of IGF-1
[21]. In animal models of ARF, administration of IGF-1
accelerates the recovery of renal function, improves renal
histology, and decreases the catabolic state [22, 23]. Acute
IGF-1 administration to humans and adult animals induces
both pre- and postglomerular vasodilation, thereby increas-
ing renal blood flow (RBF) and GFR [8, 22, 24].
We thus investigated the renal hemodynamic effects of
the acute administration of IGF-1 in a newborn rabbit
model of hypoxemia-induced ARF, which shows great
similarities to those in the developing kidney of the human
premature infant [25].
Methods
Animal experiments
The animal studies were performed according to the
guidelines of the Swiss National Science Foundation.
A total of 17 newborn, New Zealand White rabbits, 6.5±
0.3 days old [mean ± standard error of the mean (SEM),
range 5–9 days] survived the experiment and their data
were used for the final statistical analysis. All animals,
weighing 123.1±5.6 g, had been born in our own animal
facilities by spontaneous vaginal delivery and had been
suckled normally until the time of study.
All the methods have been described previously [3, 5].
Briefly, the rabbits were anesthetized by intraperitoneal
injection of 25 mg/kg body weight (BW) of sodium
pentobarbital and were artificially ventilated via tracheotomy
with an oxygen-enriched gas mixture (respiratory rate 40
breaths/min, tidal volume adjusted for age and weight).
Internal body temperature was maintained in the range of
physiological values for rabbits (i.e. 39°C). Catheters were
implanted into the femoral vessels for venous solute
infusion, arterial blood sampling, and continuous monitoring
of mean arterial blood pressure (MAP) and heart rate (HR).
Urine was sampled by bladder catheterization.
After completion of the surgical procedure, inulin and
para-aminohippuric acid (PAH) clearances were measured
throughout the experiment. From this point onward, all
animals were given a constant infusion of a modified rabbit
Ringer solution at a rate of 1 ml/h per 100 g BW [3, 5].
Experiment protocol
The experimental protocol (Fig. 1) was started on all
animals after a 90-min equilibration period by a 60-min
normoxemic control period (C), consisting of two 30-min
collections of urine, and 0.4 ml of blood withdrawn at the
midpoint of each collection. Eighty microliters were used
for immediate measurement of blood gases, glucose,
hematocrit and plasma protein levels. The red blood cells
were reconstituted in diluted human albumin and re-
infused. The remainder of the plasma was kept at −20°C
for later determination of electrolytes and renal function
markers. Results are given as means of the two urine
collections.
We then induced acute hypoxemia (period Hx) over
30 min by reducing the fractional inspiratory oxygen
concentration with a gas mixture of 1% oxygen (O2) and
90% nitrogen (N2), in order to reach a partial pressure of
arterial oxygen (PaO2) of approximately 40–50 mmHg [3,
5]. Hypoxemia was maintained at the same PaO2 level until
the end of the experiment.
The animals were then randomly divided in two age- and
weight-matched groups. All animals were given an intra-
venous (i.v.) bolus of 500 μl/100 g of their respective
treatment within 2 min, flushed with heparinized saline
solution for an additional 3 min. The treatment groups
were:
& Group NaCl: isotonic saline solution, n=8, age 6.4± 0.5
days, weight 127.9±8.7 g.
& Group IGF-1: 1 mg/kg IGF-1 (Chiron Corporation,
Emeryville, CA, USA), n=9, age 6.6±0.5 days, weight
118.8±7.5 g.
The dose of IGF-1 and way of administration were
optimized in a preliminary study performed on normoxemic
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newborn rabbits. IGF-1 at 1 mg/kg was effective on renal
function throughout the time-course of the present study,
without significantly affecting MAP [26].
Renal function was measured for three additional periods
(HxE1, HxE2, HxE3), each comprising two 30-min urine
collections, and 0.4 ml of blood was withdrawn at the
midpoint of each collection; the red blood cells were again
reconstituted and re-infused. The results from each period are
the means of the two urine collections.
Analytical procedures
Urine volume (UV) was assessed gravimetrically. Blood
gas was measured with a pH/blood gas analyzer (Blood gas
system 248, Bayer Schweiz AG, Zürich, Switzerland). The
automatic anthrone method of Wright and Gann [27] and
the method of Bratton and Marshall [28] were used for the
determination of inulin and PAH concentrations, respec-
tively (AutoAnalyzer II, Bran & Luebbe, Nordestedt,
Germany). Whole-blood glucose was assessed with a blood
glucose monitoring system (Glucometer Elite® and Ascensia
Elite® blood glucose test strips, Bayer Schweiz AG, Zürich,
Switzerland). Inulin and PAH clearances were calculated
from standard equations representing GFR and renal plasma
flow, respectively. Renal blood flow, filtration fraction (FF),
and renal vascular resistance (RVR) were derived from
standard equations as previously reported [5].
Statistical analysis
Only data from the animals that had undergone the whole
experiment were included in the final results of the renal
function parameters (n=8 and n=9, respectively) (Fig. 2).
All results are presented as means ± SEMs. P<0.05 was
considered as statistically significant.
Inter-group difference of absolute values (Table 1) during
the control and hypoxemia periods (C and Hx) was tested
by the non-parametric Mann–Whitney test. As it was not
significant for all parameters, this allowed us to pool the
results. Comparison between control and Hx periods was
then performed with the non-parametric Wilcoxon
matched-pairs signed-ranks test.
Intra-group comparisons of absolute values (Tables 2
and 3) in the two treatment groups between the hypoxemic
period Hx and experimental periods HxE1, HxE2 and
HxE3 were performed with the non-parametric Friedman
test [repeated measures analysis of variance (ANOVA)]
followed by the Wilcoxon matched-pairs signed-ranks test.
Each animal acted as its own control.
Survival rates were compared using chi-square analysis.
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Results
The two groups were similar in age, weight, all baseline
control data and all data collected during the hypoxemia
period. Therefore, we pooled data to present the overall
effects of hypoxemia on renal function (Table 1).
During the experiments relatively minor, albeit statistically
significant, changes in plasma protein levels and hematocrit
were observed. These were artifacts in the neonatal animal
experiments resulting from repeated blood sampling for PaO2
monitoring. We previously demonstrated that these changes
do not interfere with the physiologic stability of the neonatal
model [29].
Although changes were seen in PaO2, partial pressure of
arterial carbon dioxide (PaCO2) and pH levels over time,
these changes remained minor and were not physiologically
relevant (Table 2). The normocapnic hypoxemia can thus
be considered as having been well maintained in the two
groups throughout the experiment.
Hypoxemia significantly decreased MAP (−9%), GFR
(−14%), RBF (−19%), and diuresis (−12%), while RVR and
FF increased by 16% and 5%, respectively (Table 1).
Sodium chloride (NaCl) administration induced addi-
tional deterioration over time of all the parameters affected
by hypoxemia (Tables 2 and 3). RVR further increased by
92% (maximal increase at HxE3), while MAP (−17%),
GFR (−38%), RBF (−45%) and diuresis (−26%) decreased.
FF remained stable.
Although GFR, RBF and diuresis tended to decrease
during HxE1 and HxE2, IGF-1 administration completely
prevented a further rise in RVR, leading to a recovery of the
parameters of renal function during HxE3. Indeed, GFR,
RBF and diuresis increased from HxE2 to HxE3 and were
not significantly reduced when compared with the hypox-
emic control period Hx during HxE3. Meanwhile, FF
showed a tendency to decrease, although not reaching
significance (P=0.09).
Supplementary results showed that IGF-1 seemed to
have an overall protective effect against hypoxemia.
Indeed, survival rates of the pups at the end of the
experiment were 40% in the saline-treated group, compared
with 90% in the IGF-1 group. In other words, in the NaCl
group, 12 animals died before HxE3, whereas only one in
the IGF-1 group died. Chi square analysis showed a
statistically significant effect of IGF-1 treatment as early
as the second 30-min period of urine collection (Fig. 2).
Whole-blood glucose levels remained stable with saline
solution and were dramatically reduced as soon as IGF-1
administration was started, from 7.4±0.9 mmol/l to a nadir
of 3.5±1.4 mmol/l (Fig. 3).
Discussion
As we previously reported, acute normocapnic hypoxemia
in newborn rabbits was associated with a significant
increase in RVR and a concomitant decline in RBF, GFR,
MAP and diuresis [3–6, 25]. We formerly demonstrated
that renal hypoperfusion has a vasomotor origin and that
the underlying mechanisms involve the complex activation
and interaction of vasoconstrictor and vasodilator factors
acting on renal arterioles, including angiotensin II [5],
adenosine [3, 4], or NO [6].
NaCl administration showed a further deterioration of
MAP by −17% during period HxE3 compared with the
hypoxemic control period Hx. The RVR was significantly
Table 1 Absolute values of mean arterial pressure (MAP), heart rate (HR), hematocrit (Htc), plasma protein levels (Prot), blood gases [PaO2 and
partial pressure of arterial carbon dioxide (PaCO2)], systemic pH, urine volume (UV), glomerular filtration rate (GFR), renal blood flow (RBF),
filtration fraction (FF) and renal vascular resistance (RVR) in newborn rabbits during normoxemic and hypoxemic control periods. Values are
means ± SEMs. Inter-group difference was tested by the non-parametric Kruskal–Wallis test and was shown to be not significant for all
parameters, thus allowing us to pool the results. NS not significant
Parameter Normoxemic control period Hypoxemic control period P value Wilcoxon signed ranks test
C (n=17) Hx (n=17)
MAP (mmHg) 32.5±0.8 29.5±0.7 0.0003
HR (per min) 274±7 271±8 NS
Htc (%) 32.8±0.7 31.9±0.7 0.0156
Prot (g/l) 27.5±1.1 26.1±0.9 0.0005
PaO2 (mmHg) 132.8±3.0 50.4±1.6 <0.0001
PaCO2 (mmHg) 43.9±0.5 38.6±0.7 <0.0001
pH 7.43±0.01 7.46±0.01 <0.0001
UV (ml/kg per min) 0.086±0.005 0.073±0.005 0.0232
GFR (ml/kg per min) 2.00±0.12 1.72±0.13 0.0056
RBF (ml/kg per min) 18.7±1.1 15.2±1.1 0.0008
FF (%) 16.0±0.4 16.7±0.4 0.011
RVR (mmHg/ml per kg per min) 1.82±0.09 2.13±0.18 0.0202
values of mean arterial pressure (MAP), heart rate
(HR), hematocrit (Htc), pl sma protein levels (Prot), blood gases
[PaO2 and partial pressure of arterial carbon dioxide (PaCO2)],
systemic pH, urine volume (UV), glomerular filtration rate (GFR),
ren l blood flow (RBF), filtration fraction (FF) and renal vascular
resist nce (RVR) in newbo n rabbits during norm xemic and hypox-
emic control periods. Values are means ± SEMs. Inter-group difference
was tested by the non-parametric Kruskal–Wallis test and was shown
to be not significant for all p rameters, hus allowin us to po l the
results. NS not significant
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increased by a maximum of 92%, resulting in a significant
time-dependent decrease in GFR, RBF and diuresis. We
reported in the normoxemic newborn rabbit that infusion of
saline solution had no significant effect on MAP and renal
function over time, demonstrating the stability of the model
[29]. Therefore, the further deterioration of hemodynamics
and renal function observed here can be considered as a
specific effect of hypoxemia. The stable FF indicated both
pre- and postglomerular vasoconstriction, probably as the
result of a combination of actions of hypoxemia on renal
and peripheral microcirculations, as indicated by the
increase in RVR and decrease of MAP. The renal response
can thus be considered, at least partly, as a reflex
vasoconstriction of both afferent and efferent arterioles to
try and minimize changes in GFR, and hence maintain the
regulation of intrarenal vascular tone. We previously
demonstrated that the renin–angiotensin system (RAS) is
critically involved in this phenomenon in the neonatal period
in normoxemic as well as hypoxemic conditions [30, 31].
In the preterm fetal sheep, asphyxia provoked by cord
occlusion for 30 min was followed by a substantial fall in
circulating plasma levels of IGF-1 detected 4 h after
asphyxia [21]. Likewise, following 3 h of isocapnic
hypoxia in the fetal sheep, the plasma levels of IGF-1 were
reduced by approximately 35–40% 1 h after hypoxia [32].
In full-term human newborns with clinical signs of perinatal
asphyxia, serum IGF-1 levels were significantly lower than
in the control group 12–24 h after birth but also 10 days
later [19]. Administration of exogenous IGF-1 might thus
blunt any effect linked to this decrease. Indeed, in our
model, i.v. infusion of exogenous IGF-1 totally prevented
the hypoxemia-induced increase in RVR seen in the NaCl
group, with a subsequent improvement of GFR, RBF and
diuresis during HxE3 (Table 3). Meanwhile, MAP still
Table 2 Absolute values showing the effect of i.v. administration of
sodium chloride (NaCl) or IGF-1 (1 mg/kg) on mean arterial pressure
(MAP), heart rate (HR), hematocrit (Htc), plasma protein levels (Prot),
blood gases [PaO2 and partial pressure of arterial carbon dioxide
(PaCO2)] and systemic pH in hypoxemic newborn rabbits. Values are
means ± SEMs. Hx hypoxemic control period, HxE1, HxE2 and HxE3
hypoxemic experimental periods 1, 2 and 3 (Fig. 1)
Parameter NaCl (n=8) IGF-1 (n=9)
MAP (mmHg) Hx 30.4±1.0*** 28.8±0.8**
HxE1 27.6±0.9# 26.7±0.7#
HxE2 26.2±1.1# 24.6±0.8#
HxE3 25.1±1.6# 26.1±0.8#
HR (per min) Hx 286±11 258±10***
HxE1 281±11 277±12##
HxE2 292±12 285±12##
HxE3 287±11 289±12#
Htc (%) Hx 31.0±1.1*** 32.8±0.8***
HxE1 29.4±1.1# 29.6±0.6##
HxE2 28.3±1.1# 27.7±0.6##
HxE3 26.6±0.9# 27.1±0.8#
Prot (g/l) Hx 25.0±1.6 27.0±1.1***
HxE1 24.6±1.4 25.1±0.8##
HxE2 24.5±1.0 23.9±0.6##
HxE3 25.1±0.9 25.1±0.8#
PaO2 (mmHg) Hx 52.2±2.0* 48.8±2.4
HxE1 43.2±1.4# 42.3±1.1
HxE2 43.2±0.6# 41.2±1.4#
HxE3 43.4±2.0# 41.5±1.1#
PaCO2 (mmHg) Hx 38.2±1.1 39.0±1.0*
HxE1 39.9±0.6 40.0±1.8
HxE2 40.2±1.1 43.4±1.4#
HxE3 38.9±1.3 40.1±1.0
pH Hx 7.47±0.01 7.46±0.01**
HxE1 7.46±0.01 7.45±0.01
HxE2 7.45±0.01 7.41±0.01#
HxE3 7.44±0.01 7.43±0.01#
*P value of the Friedman test [non-parametric repeated measures
analysis of variance (ANOVA) for the three periods compared as a
whole to the Hx control period (*P<0.05; **P<0.01; ***P<0.001)]
#P value of further analysis for each experimental period compared
with the Hx control period with the non-parametric Wilcoxon
matched-pairs signed-ranks test (#P<0.05; ##P<0.01)
Table 3 Absolute values showing the effect of i.v. administration of
sodium chloride (NaCl) or IGF-1 (1 mg/kg) on urine volume (UV),
glomerular filtration rate (GFR), renal blood flow (RBF), filtration
fraction (FF) and renal vascular resistance (RVR) in hypoxemic
newborn rabbits. Values are means ± SEMs. Hx hypoxemic control
period, HxE1, HxE2 and HxE3 hypoxemic experimental periods 1, 2
and 3 (Fig. 1)
Parameter NaCl (n=8) IGF-1 (n=9)
UV (ml/kg per min) Hx 0.076±0.005 0.071±0.009
HxE1 0.069±0.006 0.058±0.005
HxE2 0.067±0.006 0.051±0.005#
HxE3 0.056±0.010# 0.066±0.006
GFR (ml/kg per min) Hx 1.85±0.09*** 1.61±0.23**
HxE1 1.59±0.16# 1.51±0.19
HxE2 1.47±0.16# 1.22±0.17#
HxE3 1.15±0.22# 1.30±0.19
RBF (ml/kg per min) Hx 16.0±0.9*** 14.5±2.0*
HxE1 13.3±1.4 12.8±1.8
HxE2 12.0±1.3# 11.0±1.7#
HxE3 8.9±1.5# 11.6±1.9
FF (%) Hx 16.9±0.6 16.5±0.6
HxE1 17.0±0.5 17.4±0.8
HxE2 17.1±0.3 15.7±0.8
HxE3 16.7±1.0 15.7±0.9
RVR (mmHg/ml per kg per min) Hx 1.92±0.10** 2.32±0.33
HxE1 2.28±0.27 2.45±0.33
HxE2 2.35±0.24# 2.72±0.43
HxE3 3.68±0.68# 2.69±0.43
*P value of the Friedman test (non-parametric repeated measures
ANOVA) for the three periods compared as a whole to the Hx control
period (*P<0.05; **P<0.01; ***P<0.001)
#P value of further analysis for each experimental period compared
with the Hx control period with the non-parametric Wilcoxon
matched-pairs signed-ranks test (#P<0.05)
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decreased significantly but to a lesser extent and was
relatively maintained. Although this result did not reach
statistical significance, the FF tended to decrease in the
IGF-1 group (Table 3), indicating vasodilation of renal
afferent and efferent arterioles with a tendency to a
preferential postglomerular localization. In the adult kidney,
IGF-1 receptors (IGF-1Rs) are expressed and IGF-1 is
released from glomeruli and glomerular mesangial cells in
culture [16, 17, 33, 34]. IGF-1 binds to glomerular
endothelial and epithelial cells, providing evidence for
IGF-1 action in the renal glomerulus [15]. The rabbit fetal
kidney expresses IGF-1 mRNA throughout late gestation
and at birth [13]. Yet, during the first postnatal week, the
levels of IGF-1R mRNA are low, progressively increasing
until the end of the third week [18]. This suggests that the
expression of IGF-1R is related to the postnatal acquisition
of renal function. This was the time period when our
experiments were performed. Despite the reported low
expression of IGF-1R mRNA [18], our results demonstrated
a functional expression pattern for IGF-1 and its receptors
during the rabbits’ first postnatal week of life.
These results are consistent with the observations
reported for hypoxemia alone. They strengthen the notion
of a vasomotor origin of the hypoxemia-induced insult on
the immature kidney previously reported by our group [2–
6] and suggest a role for IGF-1 deficiency in this complex
phenomenon. In anesthetized adult rats given IGF-1,
Baumann et al. reported an increase in GFR, renal plasma
flow and diuresis by 35%, 100% and 300%, respectively,
whilst RVR decreased by 50%. The FF was reduced,
indicating predominant efferent vasodilation by IGF-1 [35].
Using the in vitro blood-perfused rat juxtamedullary
nephron preparation, Tönshoff et al. demonstrated that the
renal vascular effects of IGF-1 involve mainly the activation
of two endogenous vasodilators, namely NO and vaso-
dilatory prostaglandins (PGs). Addition of IGF-1 to the
perfusate resulted in dose-dependent vasodilation of the
preglomerular microvasculature that was totally inhibited by
the NO synthase (NOS) inhibitor L-NAME [24]. It was also
demonstrated that IGF-1 perfusion induced a direct increase
in the concentration of NO in the renal microvasculature,
regardless of the localization [24, 36]. Acute IGF-1
stimulation increased NO production in rat glomeruli
through a stimulatory effect on endothelial NOS (eNOS)
message and protein expression [36]. This response was
seen as early as 3 h after the beginning of incubation with
IGF-1, which is a time-course consistent with our experi-
ment. Our group previously demonstrated that L-NAME
administration was accompanied by a worsening of the
hypoxemia-induced renal vasoconstriction, suggesting that
endogenous NO is functionally present in the immature
kidney and that NOS activity is maintained during acute
hypoxemia [6]. Moreover, endogenous NO maintains
neonatal basal renal perfusion mainly through postglomerular
renal vascular resistance [37].
We also previously demonstrated in the same model that
the newborn’s kidney is highly sensitive to cyclooxygenase
2 (COX2) inhibition and that PGs play a key role in the
regulation of neonatal GFR [29], through a rapid increase
of COX2 renal expression during the first two postnatal
weeks [38, 39]. Prostaglandin synthesis inhibition with
indomethacin completely blocked the IGF-1-induced in-
crease in GFR in vitro and in vivo [24, 40, 41]. Although
direct stimulation of PG production by IGF-1 has not been
described in renal cells, IGF-1 has been shown to stimulate
PGE2 production indirectly in mesangial cells in culture by
enhancing the interleukin-1β signaling pathway, which
results in an increase in the activity of COX2 [42].
Therefore, we can assume that the stimulating effect of
IGF-1 on both productions of NO and PGs was functional
in our study and may be, at least in part, responsible for the
vasodilation elicited by IGF-1.
Surprisingly, in contrast to these results, we reported that
IGF-1 infusion in normoxemic newborn rabbits does not
vasodilate, but rather vasoconstricts, the immature kidney
[26]. This has already been reported in the fetal lamb,
where IGF-1 infusion was associated with a marked
increase in the activity and levels of renin in fetal plasma
[43]. This might be the case in normoxemia, as the RAS is
very active in the neonatal period [26, 44]. However, we
also previously demonstrated that hypoxemia leads to a
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state of intense RAS activation in this neonatal model [5,
44]. Additional vasoconstriction through IGF-1-induced
secondary RAS activation may not have been possible
here, and the vasodilatory NO- and PG-mediated activity of
IGF-1 would have prevailed.
Whole-blood glucose levels were significantly decreased
(Fig. 3). This well-described side effect of IGF-1 infusion
may be explained by increased peripheral glucose use and
inhibition of hepatic gluconeogenesis [45, 46]. It has been
reported that glucagon increases GFR in adult dogs and
humans but has no effect on the GFR of fetal sheep [47].
Contrariwise, L-glucose infusion in rats leads to a decrease
in GFR, yet D-glucose has no effect [48]. Finally, serum
IGF-1 concentrations not stimulating total body glucose
disposal could affect renal hemodynamics, suggesting a
direct role of IGF-1 receptor-mediated events independent
of glucose metabolism [35]. In view of these conflicting
results, we assumed that IGF-1-induced hypoglycemia in
our newborn model may not have directly interfered with
renal function. The metabolic effect of IGF-1 could then be
regarded as evidence of IGF-1 efficiency and IGF-1
receptor activity.
In this study, we have demonstrated that exogenous IGF-1
administration to hypoxemic newborn rabbits can also
prevent death from ARF (Fig. 2), despite low glucose blood
levels and a decrease in blood pressure. These results are in
contrast with findings by Fernandez et al., where IGF-1
administration increased the mortality rate of adult rats
subjected to renal ischemia via bilateral renal pedicle
occlusion for 75 min [49]. However, the ARF model was
not identical, and the animals were adults, thus making it
difficult for it to be compared with our study. A difference
in the severity of ischemia-induced renal failure cannot be
ruled out either.
IGF-1 has recently been shown to be a direct neuro-
protective agent [50]. Apoptotic cell death induced by
hypoxia–ischemia was correlated with a decrease of IGF-1
mRNA in the neonatal rat brain [51]. IGF-1 administration
reduced hypoxia/ischemia-induced injury to the immature
brain of 7-day old rats by approximately 40% [52].
Likewise, IGF-1 protection against cell death and impaired
myelination in a neonatal rat model of white matter damage
was demonstrated [53]. Indirectly, IGF-1 also increased the
hypoxia-inducible factor 1α (HIF-1α) DNA binding activ-
ity and the survival of cultured primary neurons in 7-day
old rats [54]. HIF-1 is an oxygen-regulated transcriptional
complex that controls a large number of oxygen-regulated
genes. An increase in HIF-1α activity would result in
metabolic, angiogenic and apoptotic adaptive responses,
contributing to neuroprotection [52, 55]. HIF-1α accumu-
lation and HIF-1 target gene activation were triggered by
systemic administration of IGF-1 in the adult rat brain [55].
Because the level of hypoxia was profound in our model
(1% oxygen), we can speculate that the neuroprotective
action of IGF-1 played a role in the increase of survival rate
seen in our model.
Finally, besides the positive influence of partial recovery
of renal function, the beneficial effect of IGF-1 on survival
may also result from a chronotropic effect of IGF-1, as
heart rate statistically increased during IGF-1 infusion.
Direct inotropic effects of IGF-1 have been described in
neonatal rat cardiomyocytes in vitro, demonstrating the
sensitivity of the neonatal heart to IGF-1 [56]. In dogs
followed by telemetry, heart rate continuously increased for
approximately 90 min after treatment, whilst both systolic
and diastolic blood pressures decreased [57].
Conclusion
In conclusion, our study provided evidence that short-term
changes of renal function parameters can be achieved by
systemic infusion of IGF-1. Although hypoxemia-induced
ARF could not be totally prevented, IGF-1 elicited vasodi-
lation, thereby precluding a further hypoxemia-induced
decline in renal function. These results confirm that the
renal microvasculature in the neonatal period is sensitive to
exogenous IGF-1, even in pathogenic circumstances. Com-
bined with the high survival rate seen with IGF-1, these
results could be of clinical importance, as neonatal mortality
and morbidity rates due to ARF remain very high [2].
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